Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention
Identifieur interne : 001023 ( Main/Exploration ); précédent : 001022; suivant : 001024Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention
Auteurs : F. Grandas [Espagne] ; B. Hernández [Espagne]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2007-03.
English descriptors
Abstract
To evaluate the long‐term effects of entacapone on both mean daily ‘on’ time and health‐related quality of life (QoL) in patients with Parkinson's disease (PD) experiencing ‘end‐of‐dose’ motor fluctuations and the benefits of an early therapeutic intervention. A prospective, multicenter, observational, 12‐month study was performed with an initial 3‐month intervention phase, consisting of a phone call to half of the patients from randomly selected investigators to assess if dose adjustment was necessary. Effectiveness was determined by home diaries (‘on’ time), subscales II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire (PDQ‐8). After 3 months of treatment, 4.0% of the intervention group patients discontinued the study, versus 18.4% in the control group (P < 0.01). The improvement in ‘on’ time was significantly increased since the 3‐month visit (21%, P < 0.0001) until the end of the study (23% at 12 months, P < 0.0001). Entacapone also induced significant reductions in the UPDRS scores for subscales II and III and in the PDQ‐8 score. 11.2% of patients experienced at least one adverse reaction. This study confirms the effectiveness of entacapone in reducing motor fluctuations by increasing ‘on’ time, and in improving QoL of PD patients. An early adjustment of entacapone and levodopa doses reduces the number of treatment discontinuations during the first months of treatment.
Url:
DOI: 10.1111/j.1468-1331.2006.01635.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention</title><author><name sortKey="Grandas, F" sort="Grandas, F" uniqKey="Grandas F" first="F." last="Grandas">F. Grandas</name></author><author><name sortKey="Hernandez, B" sort="Hernandez, B" uniqKey="Hernandez B" first="B." last="Hernández">B. Hernández</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FBAAEFEF87047DF8B46548C02F3562DC6F807AAE</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1111/j.1468-1331.2006.01635.x</idno><idno type="url">https://api.istex.fr/document/FBAAEFEF87047DF8B46548C02F3562DC6F807AAE/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002711</idno><idno type="wicri:Area/Main/Curation">002370</idno><idno type="wicri:Area/Main/Exploration">001023</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention</title><author><name sortKey="Grandas, F" sort="Grandas, F" uniqKey="Grandas F" first="F." last="Grandas">F. Grandas</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology, Hospital Universitario Gregorio Marañón, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Hernandez, B" sort="Hernandez, B" uniqKey="Hernandez B" first="B." last="Hernández">B. Hernández</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Novartis Farmacéutica, S.A., Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2007-03">2007-03</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="282">282</biblScope><biblScope unit="page" to="289">289</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">FBAAEFEF87047DF8B46548C02F3562DC6F807AAE</idno><idno type="DOI">10.1111/j.1468-1331.2006.01635.x</idno><idno type="ArticleID">ENE1635</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>early intervention</term><term>entacapone</term><term>long‐term effects</term><term>quality of life</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the long‐term effects of entacapone on both mean daily ‘on’ time and health‐related quality of life (QoL) in patients with Parkinson's disease (PD) experiencing ‘end‐of‐dose’ motor fluctuations and the benefits of an early therapeutic intervention. A prospective, multicenter, observational, 12‐month study was performed with an initial 3‐month intervention phase, consisting of a phone call to half of the patients from randomly selected investigators to assess if dose adjustment was necessary. Effectiveness was determined by home diaries (‘on’ time), subscales II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire (PDQ‐8). After 3 months of treatment, 4.0% of the intervention group patients discontinued the study, versus 18.4% in the control group (P < 0.01). The improvement in ‘on’ time was significantly increased since the 3‐month visit (21%, P < 0.0001) until the end of the study (23% at 12 months, P < 0.0001). Entacapone also induced significant reductions in the UPDRS scores for subscales II and III and in the PDQ‐8 score. 11.2% of patients experienced at least one adverse reaction. This study confirms the effectiveness of entacapone in reducing motor fluctuations by increasing ‘on’ time, and in improving QoL of PD patients. An early adjustment of entacapone and levodopa doses reduces the number of treatment discontinuations during the first months of treatment.</div></front></TEI><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li><li>Communauté de Madrid</li></region><settlement><li>Barcelone</li><li>Madrid</li></settlement></list><tree><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Grandas, F" sort="Grandas, F" uniqKey="Grandas F" first="F." last="Grandas">F. Grandas</name></region><name sortKey="Hernandez, B" sort="Hernandez, B" uniqKey="Hernandez B" first="B." last="Hernández">B. Hernández</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001023 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001023 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FBAAEFEF87047DF8B46548C02F3562DC6F807AAE
|texte= Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention
}}
| This area was generated with Dilib version V0.6.23. |  |